Syncona Limited

AGM Information • Aug 6, 2024

National Storage Mechanism | Additional information

RNS Number : 4138Z

Syncona Limited

06 August 2024

Syncona Limited

Result of Annual General Meeting

6 August 2024

At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2024 Annual General Meeting' dated 3 July 2024 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 12 were proposed as Ordinary Resolutions. Resolution 13 was proposed as a Special Resolution and Resolution 14 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No	Resolution		For	Discretion	Against	Abstain (withheld)
1	Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2024, together with the Reports of the Directors and Auditors therein		487,893,906 (99.99%)	(0) (0%)	8,329 (0.01%)	516,479
2	Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors		477,577,926 (99.98%)	(0) (0%)	71,702 (0.02%)	10,769,086
3	Authorise the Directors to determine the remuneration of the Auditors		477,634,135 (99.99%)	(0) (0%)	21,314 (0.01%)	10,763,265
4	Re-elect Melanie Gee as a Director		485,153,484 (99.44%)	(0) (0%)	2,748,702 (0.56%)	516,528
5	Re-elect Julie Cherrington as a Director		487,856,391 (99.99%)	(0) (0%)	45,795 (0.01%)	516,528
6	Re-elect Cristina Csimma as a Director		487,826,744 (99.98%)	(0) (0%)	75,442 (0.02%)	516,528
7	Re-elect Virginia Holmes as a Director		485,146,832 (99.44%)	(0) (0%)	2,755,354 (0.56%)	516,528
8	Re-elect Robert Hutchinson as a Director		485,091,732 (99.42%)	(0) (0%)	2,808,954 (0.58%)	518,028
9	Re-elect Kemal Malik as a Director		485,094,236 (99.42%)	(0) (0%)	2,806,450 (0.58%)	518,028
10	Re-elect Gian Piero Reverberi as a Director		485,095,482 (99.42%)	(0) (0%)	2,806,704 (0.58%)	516,528
11		Approve the report on implementation of the Remuneration Policy for Non-Executive Directors	487,781,294 (99.97%)	(0) (0%)	123,008 (0.03%)	514,412
12		Authority to allot and issue shares, as set out in the Notice	475,216,648 (99.84%)	(0) (0%)	784,717 (0.16%)	12,417,349
13		Authorise the Company to purchase its own shares, as set out in the Notice	487,879,475 (99.99%)	(0) (0%)	27,221 (0.01%)	512,018
14		Disapply pre-emption rights, as set out in the Notice	469,084,312 (98.55%)	(0) (0%)	6,914,778 (1.45%)	12,419,624

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the UK Listing Rule 6.4.2R, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The full text of the resolutions can be found in the Notice, a copy of which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/ .

Enquiries

Syncona Limited

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7940

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona:

Syncona's p urpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUPUMURUPCGWQ